Antifungal activity of extracts from Atacama Desert fungi against *Paracoccidioides brasiliensis* and identification of *Aspergillus felis* as a promising source of natural bioactive compounds

Graziele Mendes¹², Vívian N Gonçalves¹, Elaine M Souza-Fagundes³, Markus Kohlhoff², Carlos A Rosa¹, Carlos L Zani², Betania B Cota², Luiz H Rosa¹, Susana Johann¹⁺

¹Universidade Federal de Minas Gerais, Instituto de Ciências Biológicas, Departamento de Microbiologia, Belo Horizonte, MG, Brasil
²Fundação Oswaldo Cruz, Centro de Pesquisa René Rachou, Laboratório de Química de Produtos Naturais, Belo Horizonte, MG, Brasil
³Universidade Federal de Minas Gerais, Departamento de Fisiologia e Biofísica, Belo Horizonte, MG, Brasil

Fungi of the genus *Paracoccidioides* are responsible for paracoccidioidomycosis. The occurrence of drug toxicity and relapse in this disease justify the development of new antifungal agents. Compounds extracted from fungal extract have showing antifungal activity. Extracts of 78 fungi isolated from rocks of the Atacama Desert were tested in a microdilution assay against *Paracoccidioides brasiliensis* Pb18. Approximately 18% (5) of the extracts showed minimum inhibitory concentration (MIC) values ≤ 125.0 µg/mL. Among these, extract from the fungus UFMGCB 8030 demonstrated the best results, with an MIC of 15.6 µg/mL. This isolate was identified as *Aspergillus felis* (by macro and micromorphologies, and internal transcribed spacer, β-tubulin, and ribosomal polymerase II gene analyses) and was grown in five different culture media and extracted with various solvents to optimise its antifungal activity. Potato dextrose agar culture and dichloromethane extraction resulted in an MIC of 1.9 µg/mL against *Paracoccidioides brasiliensis* Pb18. This extract was subjected to bioassay-guided fractionation using analytical C18RP-high-performance liquid chromatography (HPLC) and an antifungal assay using P. brasiliensis. Analysis of the active fractions by HPLC-high resolution mass spectrometry allowed us to identify the antifungal agents present in the *A. felis* extracts cytochalasins. These results reveal the potential of *A. felis* as a producer of bioactive compounds with antifungal activity.

Key words: rock-inhabiting fungi - Atacama Desert - *Paracoccidioides brasiliensis* - antifungal - *Aspergillus felis*

Paracoccidioidomycosis (PCM) is a human systemic mycosis endemic in Latin America (Tavares et al. 2005). Approximately 10 million people in this region are infected (Stürme et al. 2011), with 85% of cases occurring in Brazil (Andrade et al. 2005), and specific social groups, such as rural workers, being particularly affected (Shikanai-Yasuda et al. 2006). PCM is acquired by inhaling airborne propagules derived from the mycelial form of *Paracoccidioides brasiliensis* (Tavares et al. 2005) and *Paracoccidioides lutzii* (Teixeira et al. 2009). They adhere to the alveolar epithelium, where they transform into pathogenic yeasts (Torres et al. 2010).

Despite the effectiveness of treatments with currently available drugs (amphotericin B, azoles, and sulfonamides), they require long term administration protocols capable of causing toxic effects (Borges-Walmsley et al. 2002, Palmeiro et al. 2005, Shikanai-Yasuda et al. 2006, Visbal et al. 2011).

In addition, antifungal chemotherapy does not ensure the complete elimination of the fungus from the patient (Travassos & Taborda 2012). The discovery of new antifungal agents with higher efficacies and fewer side effects is needed in order to increase treatment options for this infection.

Abadio et al. (2015) using the rational combination of molecular modelling simulations and virtual screening identified compounds against thioredoxin reductase of *P. lutzii*, which is a promising target for drugs. Transcriptome is another potential experimental strategy to elucidate the mechanism of action of bioactive compounds using the change in gene expression. Argentilactone, for example, appears to be capable of modulating cellular targets by inducing oxidative stress and interfere with cell wall biosynthesis in *P. lutzii* (Araújo et al. 2016). Proteomic profile of this fungus indicated a global metabolic adaptation in the presence of argentilactone. Enzymes of important pathways were repressed in *P. lutzii*, while proteins involved in cell rescue, defense, and stress response were induced in the presence of argentilactone (Prado et al. 2015).

Rock-inhabiting fungi are among the most stress-tolerant organisms on Earth, able to cope with the variety of stressors associated with bare rocks in environments of hot and cold extremes (Tesei et al. 2012). These surfaces are unique habitats where rapid changes in radiation, temperature, water and nutrient availability represent a challenge to microbial survival in different environments across the world (Gueidan et al. 2008).

The Atacama Desert may be the oldest desert on Earth (Azua-Bustos et al. 2012). Atacama’s long-stand-
ing aridity adds value to the study of biological adaptations, since that, organisms have been exposed to challenging environmental conditions for sufficiently long to bear witness to evolution and natural selection processes (Wierzchos et al. 2013). It is believed that species adapted to live in such environments constitute potential sources of enzymes with special characteristics and novel genes with possible industrial applications (Dalmasso et al. 2015).

The present study aimed to evaluate the activity of crude extracts from a collection of fungi isolated from the Atacama Desert against the human pathogenic fungus *P. brasiliensis*. Extract of the strain UFMGCB 8030 showed outstanding antifungal activity against this fungus of medical importance, and thus it was selected for further investigation.

**MATERIALS AND METHODS**

**Fungal material** - The 78 fungal isolates used in this study were obtained from rocks collected in the Atacama Desert (Gonçalves et al. 2015). These fungi have been deposited in the Collection of Microorganisms and Cells of the Federal University of Minas Gerais (UFMG), Brazil, under codes UFMGCB 8010-8090 (Table I).

**Fungal cultivation and preparation of extracts for biological assays** - All fungal isolates were cultivated and extracts prepared according to protocols established by Rosa et al. (2013). A stock solution of each extract was prepared in dimethyl sulfoxide (DMSO) (Merck, USA) at a concentration of 100 mg/mL and stored at -20°C.

Extract of sterile yeast malt medium (YM) (0.3% yeast extract, 0.3% malt extract, 0.5% peptone, 2% glucose, and 2% agar), generated using the same extraction protocol, was used as a control in the screening procedure.

**Antifungal assay** - Fungal isolate and inoculum - Antifungal activity of the extracts was evaluated using *P. brasiliensis* Pb18 (Fungi Collection of the Faculty of Medicine of São Paulo University, Brazil). Isolate Pb18 belongs to the cryptic phylogenetic species S1 (Matute et al. 2006) and was maintained at the Microbiology Department of the UFMG by weekly transfer onto solid yeast peptone dextrose medium (1% yeast extract, 0.1% peptone, 1% dextrose, and 2% agar) at 37°C. Isolated Pb18 cells were suspended in sterile saline and the transmittance of the resulting suspension at a wavelength of 530 nm was adjusted to 70% (1.5 × 10⁶ cells/mL) using a spectrophotometer (SP-22; Biospectro, Brazil). The yeast-cell stock suspension was diluted in RPMI-1640 broth, 10 two-fold serial dilutions of the selected extracts, ranging from 500.0-0.9 µg/mL, were tested. DMSO (0.5% v/v) was used as a control for toxicity and itraconazole (0.05-0.0005 µg/mL) as a susceptibility control. The MIC was considered to be the lowest concentration completely inhibiting Pb18 growth compared to the growth control, expressed in µg/mL. All tests were performed in duplicate in three independent experiments.

**Determination of MIC** - Microdilution assays were performed using the same conditions as those described for the antifungal activity screen (CLSI 2008, Johann et al. 2010). By dilution in RPMI-1640 broth, 10 two-fold serial dilutions of the selected extracts, ranging from 500.0-0.9 µg/mL, were tested. DMSO (0.5% v/v) was used as a control for toxicity and itraconazole (0.05-0.0005 µg/mL) as a susceptibility control. The MIC was calculated as a percentage according to the following equation where OD signifies optical density:

\[
\% \text{ inhib.} = \left( \frac{\text{OD of negative control well} - \text{OD of sample tested}}{\text{OD of negative control well}} \right) \times 100
\]

Extracts demonstrating 70% inhibition of isolate Pb18 growth were considered active and subjected to a minimum inhibitory concentration (MIC) assay.

**Molecular identification** - The DNA extraction protocol and amplification of the internal transcribed spacer (ITS) region, achieved using the universal primers ITS1 and ITS4 (White et al. 1990), have been described by Rosa et al. (2009). Amplification of β-tubulin (Glass & Donaldson 1995) and ribosomal polymerase II genes (RPB2) (Houbraken et al. 2012) was performed with Bt2a/Bt2b and RPB2-5F-Pc/RPB2-7CR-Pc 7CR primers, respectively, according to protocols established by Godinho et al. (2013). To achieve species-rank identification based on ITS, β-tubulin, and RPB2 data, consensus sequences were aligned using all sequences of related species retrieved from the National Center for Biotechnology Information GenBank database using the Basic Local Alignment Search Tool (Altschul et al. 1997). The sequences obtained were subjected to ITS, β-tubulin, and RPB2-based phylogenetic analyses using comparisons with sequences of type species deposited in GenBank, with estimations calculated by MEGA v.5.0 (Tamura et al. 2011). The maximum composite likelihood method was employed to estimate evolutionary distances, with bootstrap values calculated from 1,000 replicate runs. Information concerning fungal classification generally follows Kirk et al. (2008) and the MycoBank (mycobank.org) and Index Fungorum (indexfungorum.org) databases.

**Morphological identification** - Macroscopic fungal parameters (colony colour and texture, border type, and radial growth rate) and colony diameters were observed on Czapek yeast autolysate (CYA) (0.5% w/v yeast extract, 3.5% w/v Czapek, 2 w/v agar) and malt extract agar (MEA) [2% w/v malt extract, 0.1% w/v peptone, 2% w/v glucose (HiMedia, India)]. Three-point inoculations...
TABLE I  
Minimum inhibitory concentrations (MIC) of extracts of fungi isolated from Atacama Desert rocks against *Paracoccidioides brasiliensis* Pb18

| Fungal species | UFMGCB$^a$ | MIC (µg/mL) |
|----------------|------------|-------------|
| Alternaria cf. arborescens | 8010 | 500.0 |
| Aspergillus felis | 8011 | 250.0 |
| Alternaria sp. 1 | 8012 | 500.0 |
| Alternaria sp. 2 | 8013 | 500.0 |
| Cladosporium halotolerans | 8014 | - |
| Neosartorya cf. udagawae | 8015 | 125.0 |
| Cladosporium cf. cladosporioides | 8017 | 500.0 |
| A. cf. arborescens | 8018 | - |
| A. felis | 8019 | 500.0 |
| Hypoxylon cf. trugodes | 8020 | 500.0 |
| N. cf. udagawae | 8021 | 62.5 |
| Fusarium oxysporum | 8023 | - |
| A. felis | 8024 | 31.2 |
| A. felis | 8025 | - |
| A. felis | 8026 | 31.2 |
| Eupenicillium javanicum | 8027 | 500.0 |
| Cladosporium cf. oxysporum | 8028 | - |
| Aspergillus sp. | 8029 | - |
| A. felis | 8030 | 15.6 |
| Aspergillus lentulus | 8031 | 500.0 |
| Neosartorya sp. 2 | 8032 | 500.0 |
| F. oxysporum | 8033 | 500.0 |
| E. javanicum | 8034 | 500.0 |
| A. lentulus | 8035 | - |
| Penicillium cf. puvillorum | 8036 | - |
| Neosartorya sp. 2 | 8037 | 500.0 |
| E. javanicum | 8038 | - |
| Neosartorya sp. 2 | 8039 | 500.0 |
| A. felis | 8040 | - |
| C. halotolerans | 8041 | - |
| C. halotolerans | 8042 | - |
| Penicillium crysogenum | 8043 | 500.0 |
| Didymellaceae sp. | 8044 | - |
| P. crysogenum | 8045 | 500.0 |
| Aspergillus persii | 8046 | - |
| Aspergillus westerdijkiae | 8047 | 500.0 |
| Cladosporium cf. gossypiiocola | 8048 | - |
| P. crysogenum | 8049 | 500.0 |
| Macroventuria cf. anomachaeta | 8050 | - |
| Penicillium cf. citrinum | 8051 | - |
| P. cf. citrinum | 8052 | - |
| P. crysogenum | 8053 | - |
| P. crysogenum | 8054 | - |
| P. crysogenum | 8055 | 500.0 |
| C. halotolerans | 8056 | - |
| P. crysogenum | 8057 | 500.0 |
| Aspergillus sydowii | 8058 | - |
| P. cf. citrinum | 8059 | - |
| P. cf. citrinum | 8060 | - |
| Devriesia sp. | 8061 | - |
| P. cf. citrinum | 8062 | - |
| Neosartorya sp. 2 | 8063 | - |
| Neosartorya sp. 2 | 8064 | - |
| Neosartorya sp. 2 | 8065 | - |
| Neosartorya sp. 1 | 8066 | - |
| Neosartorya sp. 1 | 8067 | - |
| Neosartorya sp. 2 | 8068 | - |
| Neosartorya sp. 2 | 8069 | - |
| C. halotolerans | 8070 | - |
| Neosartorya sp. 2 | 8071 | - |
| Neosartorya sp. 2 | 8072 | - |
| P. cf. citrinum | 8073 | - |
| P. crysogenum | 8074 | 500.0 |
| C. halotolerans | 8075 | - |
| C. cf. gossypiiocola | 8076 | - |
| C. halotolerans | 8077 | - |
| P. cf. citrinum | 8078 | - |
| Neosartorya cf. udagawae | 8079 | - |
| P. cf. citrinum | 8080 | - |
| P. crysogenum | 8081 | - |
| Pseudogymnoascus cf. | 8082 | - |
| Cladosporium cf. | 8083 | - |
| Cladosporium cf. | 8084 | - |
| Cladosporium cf. | 8085 | - |
| A. cf. arborescens | 8086 | - |
| C. halotolerans | 8087 | - |
| P. cf. citrinum | 8089 | 500.0 |
| P. cf. citrinum | 8090 | - |

$^a$: Collection of Microorganisms and Cells of the Federal University of Minas Gerais, Brazil; -: no antifungal activity. Bold values: good antifungal activity.
of the fungus UFMGCB 8030 were incubated for seven days in the dark at 25°C. Fungal reproductive structures were produced by micromulture technique, stained with lactophenol cotton blue (0.05% w/v), and evaluated under an optical microscope (DM750, Leica, Germany) at 40X magnification (Klich 2002).

Cultivation and extraction of UFMGCB 8030 using different culture media - The fungus UFMGCB 8030 was grown on the following five culture media in order to evaluate the antifungal activity of its extracts: potato dextrose (PDA) [2% w/v glucose, 30% w/v potato infusion (HiMedia)], YM, MEA, corn meal (HiMedia), and minimal medium containing 6.98 g/L K2HPO4, 5.44 g/L KH2PO4, and 4.1 g/L (NH4)2SO4, and supplemented with 5, 10, 15, 20, and 30 g/L glucose. The cultures were incubated at 25 ± 2°C for 15 days and extracted with ethanol (Vetec, Brazil) for 24 h at ambient temperature. After filtration, the organic phase was concentrated on a rotary evaporator. Residual solvent was removed with a SpeedVac system (Savant SPD 121P, Thermo Scientific, USA) at 40°C to yield crude extracts.

Production of UFMGCB 8030 extracts using different solvents - UFMGCB 8030 was grown on PDA medium at 25 ± 2°C for 15 days, with cultures being subjected to extraction three times at 48 h intervals using 20 mL of hexane, dichloromethane (DCM), ethyl acetate or ethanol (all Vetec). The extracts were obtained by the procedure described above.

Cytotoxicity assay - The VERO (African green monkey kidney cells) lineage was used as a model of normal cells. This lineage was maintained in the logarithmic phase of growth in Dulbecco’s modified Eagle’s medium supplemented with 100 IU/mL penicillin and 100.0 µg/mL streptomycin enriched with 5% foetal bovine serum. VERO cells were maintained at 37°C in a humidified incubator with 5% CO2 and 95% air. The medium was changed twice weekly and the cells were regularly examined and used until 20 passages. Vero cells were seeded at a density of 1 × 104 cells before being pre-incubated for 24 h at 37°C to allow for their adaptation prior to addition of the test sample. The extract was dissolved in DMSO (0.5% v/v) before dilution and tested over a range of concentrations (8 nonserial dilutions from 100-1.5 µg/mL). All cell cultures were incubated in a humidified 5% CO2/95% air atmosphere at 37°C for 48 h. The negative control comprised treatment with 0.5% v/v DMSO. Controls included drug-containing medium (background) and drug-free complete medium. Drug-free complete medium was used as a control (blank) and was treated in the same way as the drug-containing media. Results were expressed as a percentage of inhibition of cell viability compared to the 0.5% DMSO control and were calculated as follows: % inhibition of cell viability (%) = 100 - (mean OD treated - mean OD background)/(mean OD untreated culture, i.e., 0.5% DMSO - mean OD blank wells) x 100. Interactions between compounds and media were estimated on the basis of variations between drug-containing media and drug-free media to avoid false-positives or false-negatives (Monks et al. 1991). All samples were tested in triplicate in two independent experiments.

Chromatographic separation of UFMGCB 8030 DCM extract and identification of active compounds - Analytical chromatography was performed on a reversed-phase high-performance liquid chromatography (RP-HPLC) system (Shimadzu, Japan) equipped with a manual injector, two pumps (LC-10A), and a diode array detector (SPD-M10A). DCM extract (500 µg) was injected into an analytical HPLC column [Shim-pack ODS, 4 µm, 3.9 × 150 mm (Shimadzu)] and eluted at a flow rate of 1 mL/min using a gradient of 15-100% acetonitrile (ACN) in water for 16 min, followed by 100% ACN for 8 min. The effluent was collected in a 96-well plate (300 µL per well in 80 wells) using a fraction collector (SF2120; Advantec MFS, USA). The experiment was repeated four times and the plates obtained were dried in a SpeedVac vacuum centrifuge at 40°C. Fractions from two plates were dissolved in 100 µL RPMI medium containing 0.5% v/v DMSO before being transferred to fresh plates for the P. brasiiliensis Pb18 bioassay. Fractions showing 70% inhibition of isolate Pb18 growth were considered active.

Active compounds were dissolved by addition of ACN to the appropriate wells prior to liquid chromatography-mass spectrometry (LC-MS) [tandem MS (MS/MS)] analysis. This was performed on a Nexera UHPLC system (Shimadzu) coupled to a maXis ETD high-resolution ESI-QTOF mass spectrometer (Bruker, USA) and controlled by the Compass 1.5 software package (Bruker). Fractions (20 µL) were injected into a Shim-Pack XR-ODS III column [C18, 2.2 µm, 2.2 × 200 mm (Shimadzu)] at 40°C using a flow rate of 200 µL/min. The components of the mobile phase, A and B (0.1% formic acid in water and ACN, respectively), formed an eluent gradient as follows: 5% B for the initial 0.5 min, then a linear gradient to 100% B over 12.5 min, and a final hold for 1 min of 100% B. Ultraviolet chromatograms were recorded at wavelengths of 214 and 254 nm. The mass spectra were acquired in positive mode at a spectra rate of 2 Hz. Ion-source parameters were set to 500 V end plate offset, 4,500 V capillary voltage, 2.0 bar nebuliser pressure, and 8.0 L/min and 200°C dry gas flow and temperature, respectively. Data-dependent of precursor fragmentation was performed at collision energies of 40 eV. Ion cooler settings were optimised within an m/z range of 40-1,000 using a solution of 10 mM sodium formate in 50% 2-propanol for calibration. Mass calibration was achieved by an initial ion-source infusion of 20 µL calibration solution and post-acquisition recalibration of the raw data.

Compound detection was performed by chromatographic peak analysis with subsequent formula determination according to exact mass and isotope pattern (MSI) and database comparison of compound fragment spectra (MS2). An in-house database of standard compounds and the public spectra database MassBank (Horai et al. 2010) served as sources of reference ESI fragment spectra.

LC-MS mass data files were used to identify the active compounds from KNApSack and SciFinder/Chemical Abstracts Service databases. Manual interpretation of MS/MS spectra was also performed using the MassBank database.
RESULTS

When the 78 extracts of fungi obtained from rocks in the Atacama Desert were tested at a single concentration (500.0 µg/mL) against *P. brasiliensis* Pb18 35% were found to inhibit 70% of growth. These were considered to be active and their MICs were determined. Approximately 18% (5) of these active extracts exhibited MICs ≤ 125.0 µg/mL (Table I). UFMGCB 8030 extract demonstrated the lowest MIC with a value of 15.6 µg/mL followed by those of isolates UFMGCB 8024 and UFMGCB 8026, with values of 31.2 µg/mL, and UFMGCB 8021, with an MIC of 62.5 µg/mL. The fungal isolates have been identified based on ITS sequence analysis by Gonçalves et al. (2015), being grouped into 30 species belonging to 13 genera. The fungi providing the most active extracts in the present work were *Neosartorya* cf. *udagawae* (UFMGCB 8015 and 8021, with MICs of 125.0 and 62.5 µg/mL, respectively) and *Aspergillus felis* (UFMGCB 8024, 8026, and 8030, with MICs of 31.2-15.6 µg/mL) (Table I). Among the most active extracts, *A. felis* UFMGCB8030 was of particular interest, showing promising activity against *P. brasiliensis* Pb18 (MIC = 15.6 µg/mL). Thus, a more detailed study to identify both this fungus and the active compounds in its extract was performed.

Although the ITS-based identification of *A. felis* UFMGCB 8030 gave satisfactory results (Gonçalves et al. 2015), we also sequenced its β-tubulin and RPB2 (Fig. 1). A combination of phylogenetic evaluation (Fig. 1) and analysis of micro and macro-morphological features (Fig. 2) increased the degree of confidence in this identification. The ITS nucleotide sequence showed 100% query coverage and 100% similarity with that of *A. felis* (GenBank accession KF558318). In addition, the β-tubulin and RPB2 sequences of this isolate shared 84% and 100% query coverage and 99% and 98% of similarity, respectively, with the corresponding *A. felis* sequences (GenBank accessions KJ914694 and KJ914735, respectively). ITS, β-tubulin, and RPB2 references or type species sequences were retrieved from GenBank and used in a neighbour-joining phylogenetic analysis with 1,000 bootstrap replicates (Fig. 1). This approach revealed distinct clustering of the organism of interest in this study with *A. felis*, confirming it to be the species most genetically similar to isolate UFMGCB 8030.

The following characteristics of the *Aspergillus* isolate were observed, as shown in Fig. 2: colony diameters of 5.0 and 5.5 cm after seven days at 25°C on CYA and MEA media, respectively, and sporulation on MEA at 25°C on the 14th day of culture. On CYA medium, colony texture is mostly floccose; colonies are usually white, with a cream-to-light-brown reverse, and often sporulate poorly. Furthermore, yellow soluble pigments are diffused into the agar. On MEA, colonies are somewhat velvety with greenish sporulation occurring after seven days. Colonies have a cream reverse. Conidiophores are uniseriate with greenish stipes (12 × 5.0 µm) and green globose conidia 1.5-2.5 µm in length. Phialides are 6.0 × 2.0 µm and vesicles are pyriform with a diameter of 13 mm. After taxonomic analysis using molecular and morphological methods, fungus UFMGCB 8030 was confirmed to be *A. felis* (Barrs et al. 2013).

In the present study, the production of bioactive compounds was assessed by varying certain culture conditions of *A. felis* UFMGCB 8030 and testing the resulting extracts with a *P. brasiliensis* bioassay. In regard to culture media,
the most striking results were obtained with extracts from fungi cultivated on PDA (MIC = 7.8 µg/mL) followed by those from YM and corn meal cultures (MIC = 15.6 µg/mL). On MEA medium, the MIC of the ethanol extract was 62.5 µg/mL (Table II). Extracts obtained after cultivation of this isolate on minimal medium supplemented with glucose showed no antifungal activity against Pb18.

As the ethanolic extract of A. felis UFMGCB 8030 grown on PDA demonstrated the lowest MIC, this medium was used to identify the optimal solvent for the production of extracts with the highest antifungal activity. The extract obtained using DCM was found to be the most active against P. brasiliensis Pb18 (MIC = 1.9 µg/mL), followed by that produced with ethanol (MIC = 7.8 µg/mL). Extracts prepared with ethyl acetate and hexane were only minimally active (with MICs of 500.0 and 250.0 µg/mL, respectively) (Table III). The PDA/DCM A. felis UFMGCB 8030 extract did not show cytotoxicity at the concentrations tested when assayed with Vero cells, demonstrating that this extract exhibits some selectivity towards fungal cells compared to mammalian cells.

The PDA/DCM extract was then subjected to bioassay-guided fractionation using RP-HPLC and a P. brasiliensis assay (Fig. 3). The active fractions were analysed by HPLC-high resolution mass spectrometry (HRMS) with electrospray ionisation in positive-ion mode to obtain accurate mass measurements. A tentative identification based on the resulting mass spectra was achieved by manual verification using SciFinder and KNApSAcK data. The HRMS data corresponding to active fraction 1 consisted of m/z signals at 584.249 [M+H]+, 464.243 [M+H]+, and 518.214 [M+Na]+ that were tentatively identified as known compounds pyripyropene A (Omura et al. 1993), rosellichalasin (Kimura et al. 1989), and cytochalasin E (Aldridge et al. 1972), cytochalasin Kasp (Kimura et al. 1989), or aspochalasin E (Steyn et al. 1982), respectively. Active fraction 1 comprised multiple compounds, but the effective identification of these based on patterns of substitution was not possible due to a lack of information in the literature. The resulting formulas obtained from the fractions 2-4 did not match against SciFinder and KNApSAcK database to search for known metabolites. It could be hypothesised that these fractions can contain metabolites that were not previously isolated from Aspergillus species.
DISCUSSION

In the present work, the DCM extract of *A. felis* UFMGCB 8030 displayed promising activity against *P. brasiliensis* Pb18, although in a previous screen with *Candida albicans*, *Candida krusei*, and *Cladosporium sphaerospermum* it was shown to be inactive (Gonçalves et al. 2015). Although this fungus has previously been identified using ITS sequences (Gonçalves et al. 2015), in this work the identity of isolate UFMGCB 8030 was confirmed using molecular, morphological, and phylogenetic methodologies. According to Barrs et al. (2013), species belonging to the *Aspergillus* section *Fumigati*, cannot be identified only on the basis of morphological aspects only, therefore the use of other approaches for the identification of such organisms is key. Barrs et al. (2013) recently described the identification of *A. felis* in human and animal hosts (dogs and cats) with invasive aspergillosis. The isolation of this fungus from environmental samples was first reported by our group, as a result of an investigation of Atacama Desert’s rock samples (Gonçalves et al. 2015).

In fungi, the biosynthesis of secondary metabolites is regulated in response to nutrient availability or as a result of changes in the environment or developmental phase (Sanchez & Demain 2002, Zain et al. 2011). Altering the media used to culture microorganisms can enhance the production of bioactive compounds (Abdel-Fattah & Olama 2002). A good understanding of the role of culture conditions in the biosynthesis of metabolites may lead to improved exploitation of microorganisms-derived compounds (Miao et al. 2006). The ethanol extract obtained by cultivation of *A. felis* UFMGCB 8030 on PDA resulted in the strongest effect, i.e., the lowest MIC, in an evaluation of culture media, while minimal medium failed to provide conditions suitable for the production of antifungal compounds against Pb18. Bhattacharyya and Jha (2011) showed that in salt-rich media such as Czapek-Dox, the growth and antimicrobial activity of an *Aspergillus* strain was lower than that observed using a complex medium such as PDA. In addition, Mathan et al. (2013) demonstrated that low-nutrient medium has a detrimental effect on mycelial growth and metabolite profile in *Aspergillus terreus*. This suggests that in salt-rich or nutrient-poor media, mycelial growth interferes with the production of antifungal metabolites by *Aspergillus* spp.

As *A. felis* was described only very recently, we were unable to find any records in the literature concerning investigation of its secondary metabolites, a fact that encouraged us to determine the compounds in the UFMGCB 8030 DCM extract responsible for its antifungal activity. Concerning the compounds identified in this extract, no reports of antifungal activity exist for pyripyropene, rosellichalasin, cytochalasin Kasp, or aspochalasin E. However, cytochalasin E has been tested against *Botrytis cinerea* (MIC > 100 µM), *Botrytis cinerea* (MIC = 100 µM), and *Alternaria solani* (MIC = 50 µM), showing weak antifungal activity with MIC values generally greater than 50 µM (Zhang et al. 2014). Although antifungal activity against organisms of agricultural importance has thus been documented, no investigations into the effect of the compounds identified in this work against fungi of medical interest have been carried out.

The fast tentative identification of natural products using the dereplication process can be very efficient to detect promising source of new bioactive compounds (Kildgaard et al. 2014, Petersen et al. 2014, Boruta & Bizukojc 2015). In one of the fractions displaying antifungal activity, cytochalasins were identified as the active metabolites. Cytochalasins are a group of fungal secondary metabolites with a 10-phenylhydroxindol-1-one skeleton and a macrocyclic ring and are capable of various biological activities (Qiao et al. 2011). They have been described not only in the genus *Aspergillus* (Demain et al. 1976, Udagawa et al. 2000, Lin et al. 2009, Zheng et al. 2013), but also in *Xylaria* (Silva et al. 2010), *Cladosporium* (Cafêu et al. 2005), *Arthrinium* (Wang 2015), and *Phomopsis* (Shen et al. 2014). According to Guerra et al. (2014), cytochalasins inhibit actin polymerisation and act preventing actin interaction with host cells in the fungal pathogen *Cryptococcus neoformans*. *C. neoformans* is internalised by receptor-mediated or “triggered” phagocytosis, dependent on actin recruitment. Additionally, they can act as microfilament-disrupting agents, alter cell motility, adherence, secretion, drug efflux, deformability, morphology, and size, among many other cell properties critical to neoplastic cell pathology (Van Goietsenoven et al. 2011). Rosellichalasin and cytochalasin E isolated from *Aspergillus* sp. exhibit potent cytotoxic activity against human tumour cell lines (Xiao et al. 2013). Besides these compounds, aspochalasin E shows potent activity against murine melanoma B16-F10 and human colon carcinoma HCT-116 cells (Naruse et al. 1993). Pyripyropene A acts in decrease of intestinal cholesterol absorption and cholesterol oleate levels, resulting in protection of atherosclerosis development (Ohshiro et al. 2011).

The literature contains few reports on the isolation of compounds from fungi exhibiting activity against *P. brasiliensis*. However, among these are allenesin, isolated from an *Alternaria* sp. (Johann et al. 2012), and trichothecone mycotoxins (T-2 toxin and a mixture of 8-n-isobutyrylsolaniol and 8-n-butyrylneosolaniol (Campos et al. 2011). This study indicated that fungi isolated from Atacama Desert rocks may constitute potential sources of novel bioactive compounds. *A. felis* UFMGCB 8030 produced the most active extract among those studied and its antifungal activity was enhanced by changes in culture conditions. The DCM extract of this fungus showed low cytotoxicity in preliminary tests and outstanding activity against one of the fungi responsible for PCM. Our results demonstrate the importance of further studies into the fungus *A. felis*, since the analyses presented here suggest that previously unknown bioactive compounds can be produced by this species.

REFERENCES

Abadio AKR, Kioshima ES, Leroux V, Martins NF, Maigret B, Felipe MSS 2015. Identification of new antifungal compounds targeting thioredoxin reductase of *Paracoccidioides* genus. Plos ONE 10: e0142926.
Abdel-Fattah YR, Olama ZA 2002. L-asparaginase production by *Pseudomonas aeruginosa* in solid-state culture: evaluation and optimization of culture conditions using factorial designs. *Process Biochem* 38: 115-122.

Aldridge DC, Burrows BF, Turner WB 1972. The structures of the fungal metabolites cytochalasins E and F. *J Chem Soc Chem Commun* 3: 148-149.

Achtschel SF, Madden TL, Schaffer AA, Zhang JH, Zhang Z, Miller W, Lipman DJ 1997. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res* 25: 3389-3402.

Andrade RV, Silva SP, Torres FAG, Poças-Fonseca MJ, Silva-Pereira I, Maranhão AQ, Campos EG, Moraes LMP, Jesuino RSA, Pereira M, Soares CMA, Walter ME, Carvalho MJA, Almeida NF, Brigido MM, Felipe MSS 2005. Overview and perspectives on the transcriptome of *Paracoccidioides brasiliensis*. *Rev Iberoam Micol* 22: 203-212.

Aráujo FS, Coelho LM, Silva LC, da Silva Neto BR, Parente-Rocha JA, Baílão AM, de Oliveira CM, Fernandes GR, Hénandez O, Ochoa JG, Soares CM, Pereira M 2016. Effects of argentinallactone on the transcriptional profile, cell wall, and oxidative stress of *Paracoccidioides* spp. *Plos Negl Trop Dis* 10: e0004309.

Azua-Bustos A, Urrejola C, Vicuña R 2012. Life at the dry edge: microorganisms of the Atacama Desert. *Febs Letters* 586: 2939-2945.

Barrs VR, Tineke MD, Houbraken J, Kidd SE, Martin P, Pinheiro MD, Richardson M, Varga J, Samson RA 2013. *Aspergillus felis* sp. nov., an emerging agent of invasive *Aspergillosis* in humans, cats, and dogs. *Plos ONE* 8: 1-11.

Bhattacharyya PN, Jha DK 2011. Optimization of cultural conditions affecting growth and improved bioactive metabolite production by a subsurface *Aspergillus* strain tsf 146. *Int J Appl Biol Pharm Sci* 2: 133-145.

Borges-Walmsley MI, Chen D, Shu X, Walmsley AR 2002. The pathobiology of *Paracoccidioides brasiliensis*. *Trends Microbiol* 10: 80-87.

Boruta T, Biziocko M 2015. Induction of secondary metabolism of *Aspergillus terreus* ATCC 20542 in the batch bioreactor cultures. *Appl Microbiol Biotechnol* PMID: 26603760.

Cafeu MC, Silva GH, Teles HL, Bolzani VS, Araújo AR, Young WD, Donaldson GC 1995. Development of primer sets designed for use with the PCR to amplify conserved genes from filamentous ascomycetes. *Appl Environ Microbiol* 61: 1323-1330.

Glass NL, Donaldson GC 1995. Development of primer sets designed for use with the PCR to amplify conserved genes from filamentous ascomycetes. *Appl Environ Microbiol* 61: 1323-1330.

Godinho VM, Furbino LE, Santiago IF, Pelizzari FM, Yokoya N, Pupo D, Alves TMA, Júnior PAS, Romanañ J, Zani CL, Cantrell CL, Rosa CA, Rosa LH 2013. Diversity and bioprospecting of fungal communities associated with endemic and cold-adapted macroalgae in Antarctica. *ISME J* 7: 1434-1451.

Gonzalves VN, Cantrell CL, Wedge DE, Ferreira MC, Soares MA, Jacob MR, Oliveira FS, Galante D, Rodrigues F, Alves TMA, Zani CL, Júnior PAS, Murta S, Romanañ J, Barbosa EC, Kroon EG, Oliveira JG, Gómez-Silva B, Galetovic A, Rosa CA, Rosa LH 2015. Fungi associated with rocks of the Atacama Desert: taxonomy, distribution, diversity, ecology, and bioprospection for bioactive compounds. *Environ Microbiol* 18: 232-245.

Guedian CA, Villasenor CR, Hoog GS, Gorbushina AA, Unteiner WA, Lutzoni F 2008. A rock-inhabiting ancestor for mutualistic and pathogen-rich fungal lineages. *Stud Mycol* 61: 111-119.

Guerra CR, Seabra SH, de Souza W, Rozental S 2014. *Cryptococcus neoformans* is internalized by receptor-mediated or “triggered” phagocytosis, dependent on actin recruitment. *PLoS ONE* 9: 1-10.

Horai H, Arita M, Kanaya S, Nihei Y, Ikeda T, Suwa K, Ojima Y, Tanaka K, Tanaka S, Aoshima K, Oda Y, Kakazu Y, Kusano M, Tohge T, Matsuda F, Sawada Y, Hirai MY, Nanakishi H, Ikeda K, Akimoto N, Maoka T, Takahashi H, Ara T, Sakurai N, Suzuki H, Shibata D, Neumann S, Iida T, Tanaka K, Funatsu K, Matsuura F, Soga T, Taguchi R, Saito K, Nishioka T 2010. MassBank: a public repository for sharing mass spectral data for life sciences. *J Mass Spectrom* 45: 703-714.

Houbraken J, Frisvad JC, Seifert KA, Overy DP, Tuthill DM, Valdez JG, Samson RA 2012. New penicillin-producing *Penicillium* species and an overview of section *Chrysogena*. *Persoonia* 29: 78-100.

Johann S, Cisalpino OS, Watanabe GA, Cota BB, Siqueira EP, Pizzolati MG, Zani CL, Resende MA 2010. Antifungal activity of extracts of some plants used in the Brazilian traditional medicine against the pathogenic fungus *Paracoccidioides brasiliensis*. *Pharm Biol* 48: 388-396.

Johann S, Rosa LH, Rosa CA, Perez P, Cisalpino PS, Zani CL, Cota BC 2012. Antifungal activity of altenuisn isolated from the endophytic fungus *Alternaria* sp. against the pathogenic fungus *Paracoccidioides brasiliensis*. *Rev Iberoam Microl* 29: 205-209.

Kildgaard S, Månsson M, Dosen I, Kliggaard A, Frisvad JC, Larsen TO, Nielsen KF 2014. Accurate dereplication of bioactive secondary metabolites from marine-derived fungi by UHPLC-DAD-QTOFMS and a MS/HRMS library. *Mar Drugs* 12: 3681-3705.

Kimura Y, Nakajima H, Hamasaki T 1989. Structure of rosseliolachalin, a new metabolite produced by *Rosellinia necatrix*. *Agric Biol Chem* 53: 1699-1701.

Kirk PM, Cannon PF, Minter DW, Stalpers JA 2008. *Dictionary of the fungi*, 10th ed., CAB International, Wallingford, 771 pp.

Klich MA 2002. Identification of common *Aspergillus* species, Centralbureau voor Schimmelautures, Utrecht, 116 pp.

Lin Z, Zhang G, Zhu T, Liu R, Wei H, Gu Q 2009. Bioactive cytochalasins from *Aspergillus flavipes*, an endophytic fungus associated with the mangrove plant *Acanthus ilicifolius*. *Helv Chim Acta* 92: 1538-1544.

Mathan S, Subramanian V, Nagamony S 2013. Optimization and antimicrobial metabolite production from endophytic fungi *Aspergillus terreus* KC 58297. *Euro J Exp Biol* 3: 138-144.

Matute DR, McEwen JG, Puccia R, Montes BA, San-Blas G, Bagagli E, Rauscher JT, Restrepo A, Morais F, Niño-Vega G, Taylor JW 2006. Cryptic speciation and recombination in the fungus *Para-
coccioidioides brasilensis as revealed by gene genealogies. *Mol Biol Evol* **23**: 65-73.

Miao Li, Kwong TFN, Qian P 2006. Effect of culture conditions on mycelial growth, antibacterial activity, and metabolite profiles of the marine-derived fungus *Arthrinum c.f. saccharicola*. *Appl Microbiol Biotechnol* **72**: 1063-1073.

Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Bose C, Langley J, Cronise P, Vaigro-Wolf A 1991. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. *J Natl Cancer Inst* **83**: 757-766.

Naruse N, Yamamoto H, Murata S, Sawsa Y, Fukagawa Y, Oki T 1993. Aspochalasin E, a new antibiotic isolated from a fungus. *J Antibiot (Tokyo)* **46**: 679-681.

Ohshiro T, Matsuda D, Sakai K, Deginolamo C, Yagyu H, Rudel LL, Omura S, Ishibashi S, Tomoda H 2011. Pyripyropene A, an acyl-coenzyme A: cholesterol acyltransferase 2-selective inhibitor, attenuates hypercholesterolemia and atherosclerosis in murine models of hyperlipidemia. *Arterioscler Thromb Vasc Biol* **31**: 1108-1115.

Omura S, Tomoda H, Kim YK, Nishida H 1993. Pyripyropenes, high potent inhibitors of acyl-CoA cholesterol acyltransferase produced by *Aspergillus fumigatus*. *J Antibiot (Tokyo)* **46**: 1168-1169.

Palmeiro M, Cherubini K, Urgel LS 2005. Paracoccidioidomycose - Revisão da literatura. *Sci Med* **15**: 274-278.

Petersen LM, Hoeck C, Gottfredson CH, Larsen TO 2014. Dereplication guided discovery of secondary metabolites of mixed biosynthetic origin from *Aspergillus aculeatus*. *Molecules* **19**: 10989-10921.

Prado RS, Baitão AM, Silva LC, de Oliveira CMA, Marques MF, Silva LP, Silveira-Lacerda EP, Lima AP, Soares CM, Pereira M 2015. Proteomic profile response of *Paracoccidioides lutzii* to the antifungal agent flucytosine. *Front Microbiol* **6**: 616.

Qiao k, Chooi YH, Tang Y 2011. Identification and engineering of the cytochalasin gene cluster from *Aspergillus clavatus* NRRL I. *Metab Eng* **136**: 723-732.

Rosa LH, Queiroz SCN, Moraes RM, Wang X, Technen N, Pan Z, Charles L, Cantrell CL, Wedge DE 2013. *Coniochaeta ligniaria*: antifungal activity of the cryptic endophytic fungus associated with autotrophic tissue cultures of the medicinal plant *Smallanthus sonchifolius* (*Asteraceae*). *Symbiosis* **60**: 133-142.

Rosa LH, Vaz ABM, Caligiorne RB, Campolina S, Rosa CA 2009. Endophytic fungus associated with the Antartic grass *Deschampsia antarctica* Desv. (*Poaceae*). *Polar Biol* **32**: 161-167.

Sanchez S, Demain AL 2002. Regulation of fermentation processes. *Enzyme Microb Technol* **31**: 895-906.

Shen I, Luo Q, Shen Z, Li L, Zhang X, Wei Z, Fu Y, Tan R, Song Y 2014. A new cytochalasin from endophytic *Phomopsis* sp. IFB-E060. *Chin J Nat Med* **12**: 512-516.

Shikainai-Yasuda MA, Telles Filho FQ, Mendes RP, MorettI MI 2006. Guidelines in paracoccidioidomycosis. *Rev Soc Bras Med Trop* **39**: 297-310.

Silva GH, Oliveira CM, Teles HL, Bolzani VS, Araújo AR, Pfenning LH, Young MCM, Costa-Neto CM, Haddad R, Eberlin MN 2010. Citoclasinas produzidas por *Xylaria* sp., um fungo endofítico de *Piper aduncum* (*Piperaceae*). *Quim Nova* **33**: 2083-2041.

Steyn PS, van Heerden FR, Rabie CJ 1982. Cytochalasins E and K, toxic metabolites from *Aspergillus clavatus*. *J Chem Soc B*: 541-544.

Stürme MJH, Puccia R, Goldman GH, Rodrigues F 2011. Molecular biology of the dimorphic fungi *Paracoccidioides* spp. *Fungal Biol Rev* **25**: 89-97.

Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S 2011. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. *Mol Biol Evol* **28**: 2731-2739.

Tavares AH, Silva SS, Bernardez VV, Maranhão AQ, Kyaw CM, Peças Fonseca M, Silva-Pereira I 2005. Virulence insights from the *Paracoccidioides brasiliensis* transcriptome. *Genet Mol Res* **4**: 372-389.

Teixeira MM, Theodorou RC, Carvalho MJA, Fernandes L, Paes HC, Hahn R, Mendoza L, Bagagli E, San-Blas G, Felipe MS 2009. Phylogenetic analysis reveals a high level of speciation in the *Paracoccidioides* genus. *Mol Phylogenet Evol* **52**: 273-283.

Tesei D, Marzban G, Zakhavora K, Isola D, Selbmann L, Sterflinger K 2012. Alteration of protein patterns in black rock inhabiting fungi as a response to different temperatures. *Fungal Biol* **116**: 932-940.

Torres I, Garcia AM, Hernández O, González A, MeWen JG, Restrepo A, Arango M 2010. Presence and expression of the mating type locus in *Paracoccidioides brasiliensis* isolates. *Fungal Genet Biol* **47**: 373-380.

Travassos LR, Taborda CP 2012. New advances in the development of a vaccine against paracoccidioidomycosis. *Front Microbiol* **3**: 1-6.

Udagawa T, Yuan J, Panigrahy D, Chang YH, Shah J, D’Amato RJ 2000. Cytochalasin E, an epoxide containing *Aspergillus*-derived fungal metabolite, inhibits angiogenesis and tumor growth. *J Pharmacol Exp Ther* **294**: 421-427.

Van Goitsenoven G, Mathieu V, Andolfi A, Cinnozino A, LeFrand F, Kiss R, Evidente A 2011. In vitro growth inhibitory effects of cytochalasins and derivatives in cancer cells. *Planta Med* **77**: 711-717.

Visbal G, San-Blas G, Maldonado A, Alvarez-Aular A, Capparelli MV, Murghich J 2011. Synthesis, in vitro antifungal activity and mechanism of action of four sterol hydrazine analogues against the dimorphic fungus *Paracoccidioides brasiliensis*. *Stemoids* **76**: 1069-1081.

Wang J, Wang Z, Ju Z, Wan J, Liao S, Lin X, Zhang T, Zhou X, Chen H, Tu Z, Liu Y 2015. Cytotoxic cytochalasins from marine-derived fungus *Arthrinium arundinis*. *Planta Med* **81**: 160-166.

White TJ, Bruns TD, Lee SB, Taylor J 1990. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics. In IM Innis, DH Gelfand, JJ Shinsky, TJ White (eds.), *PCR protocols: a guide to methods and applications*, Academic Press, San Diego, p. 315-322.

Wierzchos J, Davila AF, Artieda O, Câmara-Gallego B, Los Rios A, Neallson KH, Valea S, García-González MT, Ascaso C 2013. Ignimbrite as a substrate for endolithic life in the hyper-arid Atacama Desert: implications for the search for life on Mars. *Icarus* **224**: 334-346.

Xiao L, Liu H, Wu N, Liu M, Wei J, Zhang Y, Lin X 2013. Characterization of the high cytochalasin E and rosellichalasin producing-*Aspergillus* sp. nov. F1 isolated from marine solar saltern in China. *World J Microbiol Biotechnol* **29**: 11-17.

Zain ME, Razak AA, El-Sheikh HH, Soliman HG, Khalil AM 2011. Influence of growth medium on diagnostic characters of *Aspergillus* and *Penicillium* species. *Afr J Microbiol Res* **3**: 280-286.

Zhang Q, Xiao J, Sun Q, Qin J, Pescitelli G, Gao J 2014. Characterization of cytochalasins from the endophytic *Xylaria* sp. and their biological functions. *J Agric Food Chem* **62**: 10962-10969.

Zheng C, Shao C, Wu Lu, Chen M, Wang K, Zhao D, Sun X, Chen G, Wang C 2013. Bioactive phenylalanine derivatives and cytochalasins from the soft coral-derived fungus, *Aspergillus elegans*. *Mar Drugs* **11**: 2054-2068.